Cost-effectiveness of drug-eluting stents: if only all things were equal.
They reduce rates of restenosis but not mortality or infarction--so are they worth it?
Chew
Derek P B
DP
D015906:Angioplasty, Balloon, Coronary / Q000191:economics*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000191:economics*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000191:economics; D001315:Australia; D049109:Cell Proliferation / Q000187:drug effects; D020099:Coated Materials, Biocompatible / Q000191:economics*; D023903:Coronary Restenosis / Q000191:economics / Q000517:prevention & control*; D023921:Coronary Stenosis / Q000191:economics / Q000628:therapy*; D003362:Cost-Benefit Analysis; D006801:Humans; D017063:Outcome Assessment, Health Care; D017239:Paclitaxel / Q000008:administration & dosage* / Q000191:economics; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000008:administration & dosage* / Q000191:economics; D015607:Stents / Q000191:economics*
D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D020099:Coated Materials, Biocompatible; D017239:Paclitaxel; D020123:Sirolimus